Walleye Capital
AVDL

Walleye Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Walleye Capital’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,100
Closed -$169K – 4556
2025
Q3 		$169K Buy
11,100
+3,200
+41% +$41.6K ﹤0.01% 3420
2025
Q2 		$69.9K Sell
7,900
-18,300
-70% -$161K ﹤0.01% 3926
2025
Q1 		$205K Buy
+26,200
New +$219K ﹤0.01% 3240
2024
Q3 		– Sell
-109,000
Closed -$1.53M – 5270
2024
Q2 		$1.53M Buy
109,000
+107,500
+7,167% +$1.75M ﹤0.01% 2371
2024
Q1 		$25.3K Buy
+1,500
New +$22.3K ﹤0.01% 4861
2023
Q4 		– Sell
-5,900
Closed -$60.8K – 4924
2023
Q3 		$60.8K Buy
+5,900
New +$79K ﹤0.01% 4134

Other funds holding AVDL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's AVDL Position: Q4 2025 in Review

Walleye Capital sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 1,887 shares — an estimated $28.8K sold.

Walleye Capital first reported a position in AVDL in Q3 2019 and held it in 6 quarters. The position peaked at $636K in Q2 2025. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

  • Walleye Capital reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Walleye Capital sold 1,887 Avadel Pharmaceuticals shares in Q4 2025, an estimated $28.8K.
  • Walleye Capital first reported a position in Avadel Pharmaceuticals in Q3 2019 and held it in 6 quarters.
  • Walleye Capital's Avadel Pharmaceuticals position peaked at $636K in Q2 2025.
  • 207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.